Developed by Shray Alag, The Harker School
Sections: Correlations,
Clinical Trials, and HPO
Navigate: Clinical Trials and HPO
Name (Synonyms) | Correlation | |
---|---|---|
drug1256 | Darunavir/Ritonavir (DRV/RTV) Wiki | 1.00 |
drug1751 | GSK3640254 Wiki | 0.58 |
Name (Synonyms) | Correlation |
---|
Navigate: Correlations HPO
There is one clinical trial.
This is an open-label, single-sequence, multiple-dose, 3 cohort study to investigate the effects of DRV/RTV and/or ETR on the pharmacokinetics (PK) of GSK3640254 and the effects of GSK3640254 on the PK of DRV/RTV and/or ETR. This study will aid in understanding these interactions and resulting changes in exposure (if any) when given in combination with GSK3640254.
Description: Blood samples will be collected for the concentrations of GSK3640254.
Measure: Cohorts 1, 2 and 3: Area under the plasma concentration-time curve from time zero to the end of the dosing interval at steady state (AUC[0-tau]) of GSK3640254 Time: Up to Day 36Description: Blood samples will be collected for the concentrations of GSK3640254.
Measure: Cohorts 1, 2 and 3: Maximum observed concentration (Cmax) of GSK3640254 Time: Up to Day 36Description: Blood samples will be collected for the concentrations of DRV.
Measure: Cohort 1: AUC(0-tau) of DRV after co-administration with GSK3640254 Time: Up to Day 35Description: Blood samples will be collected for the concentrations of DRV.
Measure: Cohort 1: Cmax of DRV after co-administration with GSK3640254 Time: Up to Day 35Description: Blood samples will be collected for the concentrations of RTV.
Measure: Cohort 1: AUC(0-tau) of RTV after co-administration with GSK3640254 Time: Up to Day 35Description: Blood samples will be collected for the concentrations of RTV.
Measure: Cohort 1: Cmax of RTV after co-administration with GSK3640254 Time: Up to Day 35Description: Blood samples will be collected for the concentrations of ETR.
Measure: Cohort 2: AUC(0-tau) of ETR after co-administration with GSK3640254 Time: Up to Day 36Description: Blood samples will be collected for the concentrations of ETR.
Measure: Cohort 2: Cmax of ETR after co-administration with GSK3640254 Time: Up to Day 36Description: Blood samples will be collected for the concentrations of GSK3640254.
Measure: Cohorts 1 and 2: Time of maximum observed concentration (Tmax) of GSK3640254 Time: Up to Day 36Description: Blood samples will be collected for the concentrations of GSK3640254.
Measure: Cohorts 1 and 2: Plasma concentration at the end of the dosing interval (Ctau) of GSK3640254 Time: Up to Day 36Description: Blood samples will be collected for the concentrations of DRV.
Measure: Cohort 1: Tmax of DRV Time: Up to Day 35Description: Blood samples will be collected for the concentrations of DRV.
Measure: Cohort 1: Ctau of DRV Time: Up to Day 35Description: Blood samples will be collected for the concentrations of RTV.
Measure: Cohort 1: Tmax of RTV Time: Up to Day 35Description: Blood samples will be collected for the concentrations of RTV.
Measure: Cohort 1: Ctau of RTV Time: Up to Day 35Description: Blood samples will be collected for the concentrations of ETR.
Measure: Cohort 2: Tmax of ETR Time: Up to Day 36Description: Blood samples will be collected for the concentrations of ETR.
Measure: Cohort 2: Ctau of ETR Time: Up to Day 36Description: All AEs, SAEs and AEs leading to discontinuation and deaths will be assessed.
Measure: Cohorts 1, 2 and 3: Number of participants with adverse events (AEs), serious AEs (SAEs) and AEs leading to discontinuation and deaths Time: Up to Day 36Description: Blood samples will be collected for the assessment of hematology and chemistry parameters.
Measure: Cohorts 1, 2 and 3: Number of participants with abnormal laboratory parameters Time: Up to Day 36Description: Urine samples will be collected for the assessment of urinalysis parameters.
Measure: Cohorts 1, 2 and 3 : Number of participants with abnormal urinalysis parameters Time: Up to Day 36Description: Number of participants with abnormal vital signs will be assessed.
Measure: Cohorts 1, 2 and 3: Number of participants with abnormal vital signs Time: Up to Day 36Description: Number of participants with abnormal ECG parameters will be assessed.
Measure: Cohorts 1, 2 and 3: Number of participants with abnormal electrocardiogram (ECG) parameters Time: Up to Day 36Alphabetical listing of all HPO terms. Navigate: Correlations Clinical Trials
Data processed on December 13, 2020.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.
Drug Reports MeSH Reports HPO Reports